Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
$0.83
-1.2%
$0.85
$0.55
$1.66
$109.68M0.9760,164 shs468,255 shs
Avinger, Inc. stock logo
AVGR
Avinger
$0.47
$0.47
$0.36
$1.93
$1.57M1.291.35 million shsN/A
Endologix, Inc. stock logo
ELGX
Endologix
$0.07
$0.03
$0.22
$7.10
$1.41M0.731.28 million shs85,372 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$2.37
-2.1%
$4.22
$0.66
$10.77
$23.75M-1.237.68 million shs76,819 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
0.00%-5.97%-3.81%+37.58%-29.32%
Avinger, Inc. stock logo
AVGR
Avinger
0.00%0.00%0.00%0.00%-73.07%
Endologix, Inc. stock logo
ELGX
Endologix
0.00%0.00%0.00%0.00%0.00%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00%-2.87%-50.93%+524.18%+1,129.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
1.456 of 5 stars
3.71.00.00.00.61.70.0
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
3.33
Buy$6.17645.67% Upside
Avinger, Inc. stock logo
AVGR
Avinger
0.00
N/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
0.00
N/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ATOS, OBLN, AVGR, and ELGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.25 ➝ $7.50
6/5/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$4.00
4/21/2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $7.25
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/A$0.57 per shareN/A
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.21N/AN/A($4.53) per share-0.10
Endologix, Inc. stock logo
ELGX
Endologix
$143.37M0.01N/AN/A$3.56 per share0.02
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M14.94N/AN/A$0.60 per share3.95
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
Endologix, Inc. stock logo
ELGX
Endologix
-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/A-776.76%-161.38%-83.58%N/A

Latest ATOS, OBLN, AVGR, and ELGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
-$0.06-$0.05+$0.01-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
N/A
12.67
12.67
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/A
Endologix, Inc. stock logo
ELGX
Endologix
0.29
0.39
0.28
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86

Institutional Ownership

CompanyInstitutional Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
12.74%
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Endologix, Inc. stock logo
ELGX
Endologix
51.61%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
18.64%

Insider Ownership

CompanyInsider Ownership
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
8.70%
Avinger, Inc. stock logo
AVGR
Avinger
42.80%
Endologix, Inc. stock logo
ELGX
Endologix
1.30%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
8.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atossa Genetics Inc. stock logo
ATOS
Atossa Genetics
8129.17 million117.93 millionOptionable
Avinger, Inc. stock logo
AVGR
Avinger
703.31 million1.89 millionNot Optionable
Endologix, Inc. stock logo
ELGX
Endologix
52819.17 millionN/AOptionable
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable

Recent News About These Companies

InterWest Management Partners X, LLC's Net Worth
Obalon Therapeutics, Inc.
Spero Therapeutics Inc.
Renovare Environmental Inc (RENO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atossa Genetics stock logo

Atossa Genetics NASDAQ:ATOS

$0.83 -0.01 (-1.21%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.83 0.00 (-0.12%)
As of 07/3/2025 04:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Avinger stock logo

Avinger NASDAQ:AVGR

$0.47 0.00 (0.00%)
As of 07/1/2025

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Endologix stock logo

Endologix NASDAQ:ELGX

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Obalon Therapeutics stock logo

Obalon Therapeutics NASDAQ:OBLN

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.